G6PD Quantitative Test

Some medications, infections, and even certain foods can destroy your red blood cells in a matter of hours, sending you to the emergency room with severe anemia, dark urine, and jaundice. Whether this happens to you depends almost entirely on a single enzyme you were born with: G6PD (glucose-6-phosphate dehydrogenase). If your G6PD activity is low, you carry a hidden vulnerability that standard blood tests never check for.

Roughly 400 million people worldwide have G6PD deficiency, making it the most common enzyme disorder in humans. Most never find out until a crisis hits. A quantitative G6PD test measures the actual activity level of this enzyme in your red blood cells, expressed in units per gram of hemoglobin (U/g Hb) and often converted to a percentage of normal. Knowing your number before you need a risky medication is the entire point.

What G6PD Does in Your Body

G6PD is the gatekeeper of your red blood cells' defense system. It is the first and most important enzyme in a metabolic route called the pentose phosphate pathway, which is how your cells produce NADPH, a small molecule that recycles your body's main internal antioxidant, glutathione. Think of glutathione as a fire extinguisher inside each red blood cell, and NADPH as the chemical that refills it after every use.

In most of your cells, there are backup routes for making NADPH. But red blood cells have no backup. G6PD is their only source. When the enzyme works normally, red blood cells can neutralize the unstable oxygen molecules (called free radicals) that build up during infections, after certain drugs, or from eating fava beans. When the enzyme is deficient, those free radicals go unchecked, damaging the cell membrane until the cell ruptures. That rupture is called hemolysis, and when it happens to enough red blood cells at once, the result is a hemolytic crisis.

Drug-Induced Hemolytic Crises

The most dangerous practical consequence of G6PD deficiency is an acute hemolytic reaction triggered by medications. The Clinical Pharmacogenetics Implementation Consortium (CPIC) classifies drugs into risk tiers for G6PD-deficient individuals. High-risk drugs that should be avoided entirely include primaquine and tafenoquine (antimalarials used to prevent malaria relapse), rasburicase (used in cancer treatment to prevent kidney damage from tumor breakdown), dapsone, and methylene blue. Medium-risk drugs require caution and monitoring. Low-risk drugs can generally be used with standard precautions.

One oncology center that implemented routine G6PD testing before giving rasburicase found that 6.1% of patients tested were deficient. Without testing, those patients would have received a drug that could have triggered a severe hemolytic crisis on top of their cancer treatment. Knowing G6PD status changed the treatment plan in every one of those cases.

Neonatal Jaundice and Newborn Risk

G6PD deficiency is a leading cause of severe jaundice in newborns. When a baby's red blood cells break down faster than the liver can process the waste product (bilirubin), bilirubin builds up in the blood and can cross into the brain, causing permanent damage called kernicterus. A universal newborn screening program in the United States tested 5,601 infants and found that 4.0% were deficient or had intermediate enzyme activity. Early identification allowed these babies to be monitored more closely in the first days of life.

Newborn enzyme activity is naturally higher than adult levels. A Saudi Arabian study of over 58,000 newborns found that using adult cutoff values (5.7 U/g Hb) missed many partially deficient infants. The study proposed a neonatal-specific threshold of 9.9 U/g Hb (the 2.5th percentile), combined with gestational age adjustments, to catch more cases, especially in girls.

The Hidden Effect on Diabetes Diagnosis

If you have G6PD deficiency and are being monitored for diabetes, your HbA1c (hemoglobin A1c, the standard blood sugar average over three months) may be misleadingly low. This happens because G6PD-deficient red blood cells have shorter lifespans. Since HbA1c reflects sugar exposure over the life of a red blood cell, shorter-lived cells accumulate less sugar coating, producing a falsely reassuring number.

In children and adolescents with type 1 diabetes, G6PD deficiency lowered HbA1c readings by an average of 1.3 percentage points at similar blood sugar levels. That is a clinically massive gap: a true HbA1c of 8.3% could show up as 7.0% on the lab report. A large UK study of nearly 472,000 people found that undiagnosed G6PD deficiency in Black and Asian men was associated with delayed type 2 diabetes diagnosis and higher rates of microvascular complications (damage to small blood vessels in the eyes, kidneys, and nerves). The likely explanation is that artificially low HbA1c readings masked worsening blood sugar control for years.

If you have G6PD deficiency and rely on HbA1c for diabetes monitoring, you should discuss alternative measures like fructosamine (a blood test that reflects blood sugar control over a shorter, two- to three-week window) or continuous glucose monitoring with your clinician.

Inflammation and G6PD Deficiency

A study of 232 adults in Sardinia, where G6PD deficiency is common, found that deficient individuals, particularly older women, showed higher levels of inflammatory markers compared to people with normal enzyme activity. This association between G6PD deficiency and a pro-inflammatory profile is still being studied, but it suggests that the enzyme's protective role extends beyond just preventing red blood cell destruction.

Reference Ranges

G6PD activity values vary significantly between labs, assays, and populations. There is no single universal cutoff that works everywhere. The most reliable approach is to express your result as a percentage of your lab's own "adjusted male median" (AMM), which represents 100% normal activity for that specific assay and population. Your lab report should ideally show both your raw value and this percentage.

These ranges come from a large meta-analysis of labs worldwide using standard enzyme-measurement methods and Trinity-based assays. They are general orientation, not universal targets. Your lab's normal values may differ, sometimes substantially.

A US reference laboratory using a different assay (Roche/Pointe) derived an AMM of 12.7 U/g Hb, making 30% equal to 3.8 U/g Hb and 70% equal to 8.9 U/g Hb at that lab. These numbers are quite different from the Trinity-based values. Always compare your result to the reference range printed on your own lab report, not to a table from a different assay.

Why Women Need Special Attention

G6PD deficiency is X-linked, meaning the gene sits on the X chromosome. Men have one X chromosome, so they are either normal or deficient, producing a clear-cut result. Women have two X chromosomes, and due to a process called X-inactivation (where one copy of the X chromosome is randomly silenced in each cell), women who carry one copy of the variant gene end up with a mixture of normal and deficient red blood cells. Their measured enzyme activity can fall anywhere between 30% and 80% of normal, often landing in the intermediate zone that qualitative (yes/no) tests completely miss.

This matters because women with intermediate activity are still at risk of hemolysis from certain drugs, particularly tafenoquine, which stays active in the body for weeks and cannot be stopped quickly if problems arise. Quantitative testing is the only reliable way to identify these women. A qualitative test that simply reports "normal" or "deficient" will classify most carrier women as normal, leaving them unprotected.

When Results Can Be Misleading

Several situations can produce a G6PD reading that does not reflect your true baseline enzyme status:

• Recent hemolysis or recovery from infection: When your body replaces destroyed red blood cells, the new young cells (reticulocytes) carry more G6PD than mature cells. This can temporarily push a truly deficient person's result into the normal range. If you have recently been ill or had a hemolytic episode, wait until your blood counts stabilize before testing.
• Recent blood transfusion: Transfused blood from a G6PD-normal donor will mix with your own cells and raise the measured activity, masking deficiency. Test before a transfusion or wait until the transfused cells have been cleared.
• High white blood cell count: White blood cells contain G6PD. An elevated white count (from infection, leukemia, or other causes) can artificially raise the measured enzyme activity, particularly in point-of-care devices.
• Neonatal timing: Newborn G6PD activity is naturally higher than adult levels and declines during the first months of life. Testing too early with adult reference ranges can miss partial deficiency.

One Test or Serial Tracking?

Unlike most biomarkers covered on this site, G6PD activity is largely determined by your genetics. Your baseline enzyme level does not fluctuate with diet, exercise, or supplements the way cholesterol or blood sugar does. For most people, a single well-timed test, taken when you are healthy and not recovering from illness, transfusion, or hemolysis, provides a reliable lifetime classification.

There are two exceptions. First, if your initial test was done during one of the confounding situations listed above (recent illness, transfusion, high white count), you should retest once those factors have resolved. Second, newborns tested in the first days of life may benefit from a confirmatory test in early childhood, since neonatal enzyme levels run higher and may obscure mild or intermediate deficiency.

If your result falls in the intermediate zone (30 to 70% of normal), a second confirmatory test is reasonable, ideally at a different time point, to make sure the reading was not influenced by transient factors. For women whose result lands near the borderline between normal and intermediate, genetic testing can clarify whether you carry a G6PD variant and resolve ambiguity that enzyme activity alone cannot.

What to Do With Your Result

If your result is normal (above 70 to 80% of your lab's reference median), you can generally receive oxidant-stress drugs without special precaution. File the result and share it with any prescribing clinician in the future.

If your result is intermediate (30 to 70%), you should avoid high-risk drugs like tafenoquine and use medium-risk drugs only with close monitoring. Consider genetic testing to identify the specific G6PD variant you carry, since some variants carry higher hemolytic risk than others. If you rely on HbA1c for diabetes screening or monitoring, discuss alternative measures with your clinician.

If your result is deficient (below 30%), you must avoid all high-risk oxidant drugs, fava beans, mothballs (naphthalene), and certain herbal remedies. Carry this information in your medical records and consider a medical alert identifier. A hematologist can help you understand your specific variant and its implications. If you have family members who have not been tested, particularly sisters, daughters, or maternal relatives, they should be tested as well, since G6PD deficiency runs in families through the X chromosome.